Peer Exchange

EP. 1: Overview of Biosimilars in Oncology
EP. 2: Interchangeability of Biosimilars
EP. 3: Role of Immunogenicity in Biosimilars
EP. 4: Using Secondary Patents and Skinny Labels
EP. 5: Adopting Biosimilars in Clinical Practice
EP. 1: Current State of the Opioid Crisis: Multifaceted Point of View
EP. 2: Unmet Needs and the Impact of COVID-19 on the Opioid Crisis
EP. 3: Effective and Appropriate Pain Management Challenges
EP. 4: Opioid Crisis Misconceptions and Unintended Consequences
EP. 5: Risks for Accidental Opioid Overdose Seen in the Community
EP. 6: New Labeling Requirements Put Forth by the FDA for Opioids
EP. 7: Implementing Protocols, Policies, and Programs to Save Lives
EP. 8: Improving the Accessibility of Naloxone and Potential Impact
EP. 9: Normalizing the Conversation about Naloxone with the Public
EP. 10: Barriers to Naloxone Prescribing, Dispensing, and Utilization
EP. 11: December 2020 CDC Health Alert Highlights and Implementation
EP. 12: Are Recommendations Infringing Upon Practice Autonomy?
EP. 1: Relapsed/Refractory Multiple Myeloma: Disease Overview
EP. 2: Treatment Pathways for Relapsed/Refractory Myeloma
EP. 3: IV Versus Subcutaneous Daratumumab
EP. 4: Backbone Regimens for Relapsed/Refractory Myeloma
EP. 5: mAb-based Therapies for Relapsed/Refractory Myeloma
EP. 6: Novel Agents for Relapsed/Refractory Myeloma
EP. 7: Belantamab Mafodotin for RRMM
EP. 8: RRMM: Adopting Anti-BCMA Therapy into Practice
EP. 9: RRMM: Educating Pharmacists on Anti-BCMA Therapy
EP. 10: Clinical Trials of Interest in RRMM
EP. 11: Optimizing Therapy for Patients With RRMM
EP. 1: C. Difficile Risk Factors and Manifestation
EP. 2: Strains of C. Difficile
EP. 3: Managing Community-Onset C. Difficile
EP. 4: Recurrent C. Difficile
EP. 5: C. Difficile: A Differential Diagnosis
EP. 6: Testing for C. Difficile Infections
EP. 7: Screening for C. Difficile
EP. 8: C. Difficile: Clinical Practice Guidelines and Treatment Options
EP. 9: C. Difficile: Updates to Clinical Practice Guidelines
EP. 10: Selecting Therapy to Treat C. Difficile
EP. 11: C. Difficile Treatment: Fidaxomicin
EP. 12: Choosing Between Vancomycin and Fidaxomicin for C. Difficile Infections
EP. 1: Immune Thrombocytopenia Defined
EP. 2: Immune Thrombocytopenia: Risks and Impact on Patients
EP. 3: Immune Thrombocytopenia: A Differential Diagnosis
EP. 4: Initial Treatment of Immune Thrombocytopenia
EP. 5: Corticosteroids Vs IVIG for Immune Thrombocytopenia
EP. 6: Unmet Needs in the Treatment of Immune Thrombocytopenia
EP. 7: Sequencing Therapy in ITP: Current Guidelines
EP. 8: SYK Inhibitors as Immune Thrombocytopenia Treatment
EP. 9: Immune Thrombocytopenia: SYK Inhibitors and COVID-19
EP. 10: What to Know When Treating ITP With a SYK Inhibitor
EP. 11: SYK Inhibitors to Treat ITP: Clinical Implications
EP. 12: TPO-RAs as Immune Thrombocytopenia Treatment
EP. 13: Combination Therapy for Immune Thrombocytopenia Treatment
EP. 14: Immune Thrombocytopenia Treatment: Rituximab and Splenectomy
EP. 1: Comparison of Biosimilars vs Biologic Agents
EP. 2: FDA Approval Process of Biosimilars
EP. 3: Interchangeability Status in Biosimilars
EP. 4: Efficacy of Biosimilars vs Biologics
EP. 5: Role of Biosimilars in US vs Europe
EP. 6: Impact of Biosimilars on Cancer Treatment
EP. 7: Currently Available Biosimilars in the US
EP. 8: Current and Next-Generation Biosimilars in Oncology
EP. 9: Clinical Experiences for Biosimilars in Oncology
EP. 10: Biosimilar Decision-Making Process in Clinical Settings
EP. 11: Recommending Biosimilars vs Biologics: Patient Factors
EP. 12: Switching Treatment From Biologics to Biosimilars
EP. 13: Limiting Quantity of Available Biosimilars
EP. 14: Role of Clinical Pharmacists in Switching Biosimilars
EP. 15: Provider Education on Biosimilar Products
EP. 16: Raising Patient Awareness of Biosimilar Products
EP. 17: Myths and Misconceptions on Biosimilars
EP. 18: Economic Impact of Biosimilars
EP. 19: Impact of Competition of Biosimilars on Biologics